Advertisement
Singapore markets close in 2 hours

  • Straits Times Index

    3,280.98
    -12.15 (-0.37%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,269.68
    +68.41 (+0.40%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,258.97
    -2,511.82 (-3.76%)
     

  • CMC Crypto 200

    1,389.18
    +6.60 (+0.48%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,332.60
    -5.80 (-0.25%)
     

  • Crude Oil

    82.93
    +0.12 (+0.14%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.82
    -0.66 (-0.04%)
     

  • Jakarta Composite Index

    7,158.86
    -15.68 (-0.22%)
     

  • PSE Index

    6,581.11
    +8.36 (+0.13%)
     

Company News For Oct 27, 2017

Zacks Equity Research
Updated
Is (MCS) Outperforming Other Consumer Discretionary Stocks This Year?

  • Shares of Twitter, Inc. TWTR gained 18.5% after posting third quarter 2017 earnings per share of $0.02, surpassing the Zacks Consensus Estimate of a loss of $0.03

  • Shares of Ford Motor Company F rallied 1.9% after posting third quarter 2017 earnings per share of $0.43, surpassing the Zacks Consensus Estimate of $0.33

  • Bristol-Myers Squibb Company’s BMY shares plummeted 4.8% after posting third quarter 2017 earnings per share of $0.75, lower than the Zacks Consensus Estimate of $0.77

  • ABIOMED, Inc.’s ABMD shares rallied 4.8% after posting second quarter 2017 earnings per share of $0.44, surpassing the Zacks Consensus Estimate of $0.37


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Twitter, Inc. (TWTR) : Free Stock Analysis Report
 
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Ford Motor Company (F) : Free Stock Analysis Report
 
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research